Related scientific articles (all)

Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer.

Authors : Arcolia V, Journe F, Renaud F, Leteurtre E, Gabius HJ, Remmelink M, Saussez S
Year : 2017
Journal : Oncol Lett
Volume : 14
Pages : 4183-4189

A non-coding function of TYRP1 mRNA promotes melanoma growth.

Authors : Gilot D, Migault M, Bachelot L, Journe F, Rogiers A, Donnou-Fournet E, Mogha A, Mouchet N, Pinel-Marie ML, Mari B, Montier T, Corre S, Gautron A, Rambow F, El Hajj P, Ben Jouira R, Tartare-Deckert S, Marine JC, Felden B, Ghanem G, Galibert MD
Year : 2017
Journal : Nat Cell Biol
Volume : 19(11)
Pages : 1348-1357

Role of macrophage migration inhibitory factor in head and neck cancer and novel therapeutic targets: A systematic review.

Authors : Lechien JR, Nassri A, Kindt N, Brown DN, Journe F, Saussez S
Year : 2017
Journal : Head Neck
Volume : 39(12)
Pages : 2573-2584

Langerhans cell number is a strong and independent prognostic factor for head and neck squamous cell carcinomas.

Authors : Kindt N, Descamps G, Seminerio I, Bellier J, Lechien JR, Pottier C, Larsimont D, Journe F, Delvenne P, Saussez S
Year : 2016
Journal : Oral Oncol
Volume : 62
Pages : 1-10

The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene.

Authors : Van Kempen LC, Redpath M, Elchebly M, Klein KO, Papadakis AI, Wilmott JS, Scolyer RA, Edqvist PH, Pontén F, Schadendorf D, van Rijk AF, Michiels S, Dumay A, Helbling-Leclerc A, Dessen P, Wouters J, Stass M, Greenwood CM, Ghanem G, van den Oord J, Feunteun J, Spatz A
Year : 2016
Journal : Sci Transl Med
Volume : 8
Pages : 369ra177

GLI inhibitor GANT61 kills melanoma cells and acts in synergy with obatoclax.

Authors : Vlckova K, Reda J, Ondrusova L, Krayem M, Ghanem G, Vachtenheim J
Year : 2016
Journal : Int J Oncol
Volume : 49
Pages : 953-60

Classical risk factors, but not HPV status, predict survival after chemoradiotherapy in advanced head and neck cancer patients.

Authors : Descamps G, Karaca Y, R Lechien J, Kindt N, Decaestecker C, Remmelink M, Larsimont D, Andry G, Hassid S, Rodriguez A, Khalife M, Journe F, Saussez S
Year : 2016
Journal : J Cancer Res Clin Oncol
Volume : 142(10)
Pages : 2185-96

The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters.

Authors : Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van den Bulck H, Smeets A, Bechter O, Kini Bailur J, Kenis C, Laenen A, Schöffski P, Pawelec G, Journe F, Ghanem G, Wildiers H
Year : 2016
Journal : Oncotarget
Volume : 7(21)
Pages : 29977-88

p53 Reactivation by PRIMA-1 Met (APR-246) sensitises V600E/K BRAF melanoma to vemurafenib.

Authors : Krayem M, Journe F, Wiedig M, Morandini R, Najem A, Sales F, Van Kempen LC, Sibille C, Awada A, Marine JC, Ghanem G
Year : 2016
Journal : Eur J Cancer
Volume : 55
Pages : 98-110

Survey on skin-lightening practices and cosmetics in Kigali, Rwanda.

Authors : Kamagaju L, Morandini R, Gahongayire F, Stévigny C, Ghanem G, Pirotte G, Duez P
Year : 2016
Journal : Int J Dermatol
Volume : 55(1)
Pages : 45-51

SNPs at miR-155 binding sites of TYRP1 explain discrepancy between mRNA and protein and refine TYRP1 prognostic value in melanoma.

Authors : El Hajj P, Gilot D, Migault M, Theunis A, Van Kempen LC, Sales F, Fayyad-Kazan H, Badran B, Larsimont D, Awada A, Bachelot L, Galibert MD, Ghanem G, Journe F
Year : 2015
Journal : Br J Cancer
Volume : 113(1)
Pages : 91-8

Melanins and Melanogenesis: From Pigment Cells to Human Health and Technological Applications.

Authors : d Ischia M, Wakamatsu K, Cicoira F, Di Mauro E, Garcia-Borron JC, Commo S, Galván I, Ghanem G, Koike K, Meredith P, Pezzella A, Santato C, Sarna T, Simon JD, Zecca L, Napolitano A, Ito S
Year : 2015
Journal : Pigment Cell Melanoma Res
Volume : 28(5)
Pages : 520-44

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state.

Authors : Verfaillie A, Imrichova H, Atak ZK, Dewaele M, Rambow F, Hulselmans G, Christiaens V, Svetlichnyy D, Luciani F, Van den Mooter L, Claerhout S, Fiers M, Journe F, Ghanem G, Herrmann C, Halder G, Marine JC, Aerts S
Year : 2015
Journal : Nat Commun
Volume : 6(null)
Pages : 6683

Mucolytic Agents Can Enhance HER2 Receptor Accessibility for [(89)Zr]Trastuzumab, Improving HER2 Imaging in a Mucin-Overexpressing Breast Cancer Xenograft Mouse Model.

Authors : Wimana Z, Gebhart G, Guiot T, Vanderlinden B, Morandini R, Doumont G, Sherer F, Van Simaeys G, Goldman S, Ghanem G, Flamen P
Year : 2015
Journal : Mol Imaging Biol
Volume : 17(5)
Pages : 697-703

Tumour targeting and radiation dose of radioimmunotherapy with (90)Y-rituximab in CD20+ B-cell lymphoma as predicted by (89)Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab.

Authors : Muylle K, Flamen P, Vugts DJ, Guiot T, Ghanem G, Meuleman N, Bourgeois P, Vanderlinden B, van Dongen GA, Everaert H, Vaes M, Bron D
Year : 2015
Journal : Eur J Nucl Med Mol Imaging
Volume : 42(8)
Pages : 1304-14

Chronic exposure to low-dose radiation at Chernobyl favors adaptation to oxidative stress in birds.

Authors : Galván I, Bonisoli-Alquati A, Jenkinson S, Ghanem G, Wakamatsu K, Mousseau Ta, Møller AP
Year : 2014
Journal : Functional Ecology
Volume : 28
Pages : 1387-1403

Influence of paramagnetic melanin on the MRI contrast in melanoma: a combined high-field (11.7 T) MRI and EPR study.

Authors : Godechal Q, Mignion L, Karroum O, Magat J, Danhier P, Morandini R, Ghanem G, Leveque P, Gallez B
Year : 2014
Journal : Contrast Media Mol Imaging
Volume : 9(2)
Pages : 154-60

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression.

Authors : Denecker G, Vandamme N, Akay O, Koludrovic D, Taminau J, Lemeire K, Gheldof A, De Craene B, Van Gele M, Brochez L, Udupi GM, Rafferty M, Balint B, Gallagher WM, Ghanem G, Huylebroeck D, Haigh J, van den Oord J, Larue L, Davidson I, Marine JC, Berx G
Year : 2014
Journal : Cell Death Differ.
Volume : 21(8)
Pages : 1250-61

Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib.

Authors : Krayem M, Journe F, Wiedig M, Morandini R, Sales F, Awada A, Ghanem G
Year : 2014
Journal : Eur. J. Cancer
Volume : 50(7)
Pages : 1310-20

HER4 and its cytoplasmic isoforms are associated with progression-free survival of malignant melanoma.

Authors : Nielsen TO, Poulsen SS, Journe F, Ghanem G, Sorensen BS
Year : 2014
Journal : Melanoma Res.
Volume : 24(1)
Pages : 88-91